Osteoarthritis endotype discovery via clustering of biochemical marker data.

epidemiology; knee; osteoarthritis; Biomarkers; Cluster Analysis; Disease Progression; Humans; Inflammation; Bone Resorption; Cartilage, Articular; Osteoarthritis, Knee/drug therapy; Osteoarthritis, Knee; Rheumatology; Immunology and Allergy; Immunology; Biochemistry, Genetics and Molecular Biology (all); General Biochemistry, Genetics and Molecular Biology

Abstract :

[en] OBJECTIVES: Osteoarthritis (OA) patient stratification is an important challenge to design tailored treatments and drive drug development. Biochemical markers reflecting joint tissue turnover were measured in the IMI-APPROACH cohort at baseline and analysed using a machine learning approach in order to study OA-dominant phenotypes driven by the endotype-related clusters and discover the driving features and their disease-context meaning. METHOD: Data quality assessment was performed to design appropriate data preprocessing techniques. The k-means clustering algorithm was used to find dominant subgroups of patients based on the biochemical markers data. Classification models were trained to predict cluster membership, and Explainable AI techniques were used to interpret these to reveal the driving factors behind each cluster and identify phenotypes. Statistical analysis was performed to compare differences between clusters with respect to other markers in the IMI-APPROACH cohort and the longitudinal disease progression. RESULTS: Three dominant endotypes were found, associated with three phenotypes: C1) low tissue turnover (low repair and articular cartilage/subchondral bone turnover), C2) structural damage (high bone formation/resorption, cartilage degradation) and C3) systemic inflammation (joint tissue degradation, inflammation, cartilage degradation). The method achieved consistent results in the FNIH/OAI cohort. C1 had the highest proportion of non-progressors. C2 was mostly linked to longitudinal structural progression, and C3 was linked to sustained or progressive pain. CONCLUSIONS: This work supports the existence of differential phenotypes in OA. The biomarker approach could potentially drive stratification for OA clinical trials and contribute to precision medicine strategies for OA progression in the future. TRIAL REGISTRATION NUMBER: NCT03883568.

Disciplines :

Rheumatology

Author, co-author :

Angelini, Federico ; School of Computing, Newcastle University, Newcastle upon Tyne, UK

Widera, Paweł ; School of Computing, Newcastle University, Newcastle upon Tyne, UK

Mobasheri, Ali ; Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland ; Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania ; Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands ; Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China ; World Health Organization Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liege, Belgium

Blair, Joseph ; ImmunoScience, Nordic Bioscience, Herlev, Denmark

Struglics, André ; Faculty of Medicine, Department of Clinical Sciences Lund, Orthopaedics, Lund University, Lund, Sweden

Uebelhoer, Melanie ; Artialis SA, Liège, Belgium

Henrotin, Yves ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM) ; Artialis SA, Liège, Belgium

Marijnissen, Anne Ca; Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands

Kloppenburg, Margreet ; Rheumatology, Leiden Universitair Medisch Centrum, Leiden, The Netherlands ; Department of Clinical Epidemiology, Leiden Universitair Medisch Centrum, Leiden, The Netherlands

Blanco, Francisco J ; Servicio de Reumatologia, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain

More authors (6 more)

Language :

English

Title :

Osteoarthritis endotype discovery via clustering of biochemical marker data.

Publication date :

2022

Journal title :

Annals of the Rheumatic Diseases

ISSN :

0003-4967

eISSN :

1468-2060

Publisher :

BMJ Publishing Group, England

Volume :

Issue :

Pages :

666-675

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2021-221763

Funders :

IMI - Innovative Medicines Initiative

Funding text :

Competing interests ACB-J is a full-time employee and shareholder of Nordic Bioscience, a privately owned company involved in the development and commercialisation of biomarkers for fibroinflammatory disorders. YH is the founder and president of Artialis, and MU is a full-time employéé of Artialis, a spin-off company of the University of Liège. YH has also received fees from Tilman, Genequine, Seikagaku, Expanscience, Nestlé, Immubio, Biose and Labhra. CL was an employee of Merck at project start. IKH consults for Abbvie and Novartis and has received funding from Pfizer. JL is employed by and shareholder in GlaxoSmithKline. FB reports personal fees from AstraZeneca, Boehringer, Bone Therapeutics, CellProthera, Expanscience, Galapagos, Gilead, Grunenthal, GSK, Eli Lilly, Merck Sereno, MSD, Nordic, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, 4P Pharma, 4Moving Biotech and grants from TRB Chemedica, outside the submitted work. FJB reports funding from Gedeon Richter, Bristol-Myers Squibb, Sun Pharma Global FZE, Celgene, Janssen Cilag, Janssen Research & Development, Viela Bio, Astrazeneca, UCB BIOSCIENCES, UCB BIOPHARMA SPRL, AbbVie Deutschland, Merck, Amgen, Novartis Farmacéutica, Boehringer Ingelheim España, CSL Behring, Glaxosmithkline Research & Development, Pfizer, Lilly, Corbus Pharmaceuticals, Biohope Scientific Solutions for Human Health, Centrexion Therapeutics, Sanofi, TEDEC-MEIJI FARMA, Kiniksa Pharmaceuticals, Fundación para la Investigación Biomédica Del Hospital Clínico San Carlos, Grünenthal and Galapagos. MK receives consulting fees from Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR, Novartis, UCB. AM receives fees/funding from Merck, Kolon TissueGene, Pfizer, Galapagos-Servier, Image Analysis Group (IAG), Artialis, Aché Laboratórios Farmacêuticos, AbbVie, Guidepoint Global, Alphasights, Science Branding Communications, GSK, Flexion Therapeutics, Pacira Biosciences, Sterifarma, Bioiberica, SANOFI, Genacol, Kolon Life Science, BRASIT/BRASOS, GEOS, MCI Group, Alcimed, Abbot, Laboratoires Expansciences, SPRIM Communications, Frontiers Media and University Health Network Toronto.Funding The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement no 115770, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in-kind contribution. See http://www.imi.europa.eu/ and http:// wwwapproachprojecteu/.

Available on ORBi :

since 05 June 2022

Statistics

Number of views

475 (5 by ULiège)

Number of downloads

250 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet 2020;396:1711-2.
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019;393:1745-59.
Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers 2016;2:16072.
Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73:1323-30.
Safiri S, Kolahi A-A, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis 2020;79:819-28.
Zhang W, Ouyang H, Dass CR, et al. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res 2016;4:15040.
Ghouri A, Conaghan PG. Prospects for therapies in osteoarthritis. Calcif Tissue Int 2021;109:339-50.
Deveza LA, Loeser RF. Is osteoarthritis one disease or a collection of many? Rheumatology 2018;57:iv34-42.
Deveza LA, Nelson AE, Loeser RF. Phenotypes of osteoarthritis: current state and future implications. Clin Exp Rheumatol 2019;37 Suppl 120:64-72.
Karsdal MA, Christiansen C, Ladel C, et al. Osteoarthritis-a case for personalized health care? Osteoarthritis Cartilage 2014;22:7-16.
Driban JB, Sitler MR, Barbe MF, et al. Is osteoarthritis a heterogeneous disease that can be stratified into subsets? Clin Rheumatol 2010;29:123-31.
Luo Y, Samuels J, Krasnokutsky S, et al. A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis. J Orthop Traumatol 2021;22:10.
Ching K, Houard X, Berenbaum F. Hypertension meets osteoarthritis-revisiting the vascular aetiology hypothesis. Nat Rev Rheumatol 2021:1-17.
Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord 2016;17:425.
Dell'Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: data from the osteoarthritis initiative. PLoS One 2018;13:e0191045.
Mobasheri A, Saarakkala S, Finnilä M, et al. Recent advances in understanding the phenotypes of osteoarthritis. F1000Res 2019;8. doi:10.12688/ f1000research.20575.1. [Epub ahead of print: 12 Dec 2019].
Mobasheri A, van Spil WE, Budd E, et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol 2019;31:80-9.
Thudium CS, Nielsen SH, Sardar S, et al. Bone phenotypes in rheumatology-there is more to bone than just bone. BMC Musculoskelet Disord 2020;21:789.
Kim Y, Levin G, Nikolov NP, et al. Concept endpoints informing design considerations for confirmatory clinical trials in osteoarthritis. Arthritis Care Res 2020. doi:10.1002/ acr.24549. [Epub ahead of print: 20 Dec 2020].
Bonakdari H, Jamshidi A, Pelletier J-P, et al. A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening. Ther Adv Musculoskelet Dis 2021;13:1759720X21993254.
Tiulpin A, Thevenot J, Rahtu E, et al. Automatic knee osteoarthritis diagnosis from plain radiographs: a deep Learning-Based approach. Sci Rep 2018;8:1727.
Tiulpin A, Klein S, Bierma-Zeinstra SMA, et al. Multimodal machine Learning-based knee osteoarthritis progression prediction from plain radiographs and clinical data. Sci Rep 2019;9:20038.
van Helvoort EM, van Spil WE, Jansen MP, et al. Cohort profile: the applied public-private research enabling osteoarthritis clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemical markers. BMJ Open 2020;10:e035101.
Widera P, Welsing PMJ, Ladel C, et al. Multi-classifier prediction of knee osteoarthritis progression from incomplete imbalanced longitudinal data. Sci Rep 2020;10:8427.
Christian H, Nielsen AB, Thorsen-Meyer H-C. Survival prediction in intensive-care units based on aggregation of long-term disease history and acute physiology a retrospective study of the Danish national patient registry and electronic patient records articles survival prediction in intensive-care. Lancet Digit Heal 2019;1.
Pedregosa F, Varoquaux G, Gramfort A. Scikit-learn: machine learning in python. J Mach Learn Res 2011;12.
Lundberg SM, Erion G, Chen H, et al. From local explanations to global understanding with explainable AI for trees. Nat Mach Intell 2020;2:2522-5839.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
Kraus VB, Collins JE, Hargrove D, et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH oa biomarkers Consortium. Ann Rheum Dis 2017;76:186-95.
Rudzki PJ, Biecek P, Kaza M. Incurred sample reanalysis: time to change the sample size calculation? AAPS J 2019;21:28.
Fluhler E, Vazvaei F, Singhal P, et al. Repeat analysis and incurred sample reanalysis: recommendation for best practices and harmonization from the global bioanalysis Consortium harmonization team. Aaps J 2014;16:1167-74.
McInnes L, Healy J, Melville J. Umap: uniform manifold approximation and projection for dimension reduction. arXiv 2018:1802.03426.
Kraus VB, Karsdal MA. Osteoarthritis: current molecular biomarkers and the way forward. Calcif Tissue Int 2021;109:1-10.
Karsdal MA, Byrjalsen I, Alexandersen P, et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthr Cartil 2015;23:532-43.
Wang SX, Abramson SB, Attur M, et al. Safety, tolerability, and pharmacodynamics of an anti-interleukin-1/dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthritis Cartilage 2017;25:1952-61.
Oo WM, Little C, Duong V, et al. The development of disease-modifying therapies for osteoarthritis (DMOADs): the evidence to date. Drug Des Devel Ther 2021;15:2921-45.
van Spil WE, Bierma-Zeinstra SMA, Deveza LA, et al. A consensus-based framework for conducting and reporting osteoarthritis phenotype research. Arthritis Res Ther 2020;22:54.
Sohn DH, Sokolove J, Sharpe O, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther 2012;14:R7.
Werdyani S, Liu M, Zhang H, et al. Endotypes of primary osteoarthritis identified by plasma metabolomics analysis. Rheumatology 2021;60:2735-44.
Bay-Jensen AC, Mobasheri A, Thudium CS, et al. Blood and urine biomarkers in osteoarthritis-an update on cartilage associated type II collagen and aggrecan markers. Curr Opin Rheumatol 2022;34:54-60.
Bay-Jensen AC, Manginelli AA, Karsdal M, et al. Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the forward study. Osteoarthritis Cartilage 2022;30:92-9.
van der Aar E, Deckx H, Dupont S, et al. Safety, pharmacokinetics, and pharmacodynamics of the ADAMTS-5 inhibitor GLPG1972/S201086 in healthy volunteers and participants with osteoarthritis of the knee or hip. Clin Pharmacol Drug Dev 2022;11:112-22.
Loeser RF, Beavers DP, Bay-Jensen AC, et al. Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis: the intensive diet and exercise for arthritis trial (idea). Osteoarthritis Cartilage 2017;25:1822-8.
Bay-Jensen A-C, Bihlet A, Byrjalsen I, et al. Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis. Sci Rep 2021;11:6583.
Larsson S, Lohmander LS, Struglics A. An ARGS-aggrecan assay for analysis in blood and synovial fluid. Osteoarthritis Cartilage 2014;22:242-9.
He Y, Manon-Jensen T, Arendt-Nielsen L, et al. Potential diagnostic value of a type X collagen neo-epitope biomarker for knee osteoarthritis. Osteoarthritis Cartilage 2019;27:611-20.
Bay-Jensen A-C, Liu Q, Byrjalsen I, et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011;44:423-9.
Mobasheri A, Lambert C, Henrotin Y. Coll2-1 and Coll2-1NO2 as exemplars of collagen extracellular matrix turnover-biomarkers to facilitate the treatment of osteoarthritis? Expert Rev Mol Diagn 2019;19:803-12.
Kluzek S, Bay-Jensen A-C, Judge A, et al. Serum cartilage oligomeric matrix protein and development of radiographic and painful knee osteoarthritis. A community-based cohort of middle-aged women. Biomarkers 2015;20:557-64.
Kraus VB, Collins JE, Charles HC, et al. Predictive validity of radiographic trabecular bone texture in knee osteoarthritis: the osteoarthritis research Society International/ Foundation for the National Institutes of health osteoarthritis biomarkers Consortium. Arthritis Rheumatol 2018;70:80-7.
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24:237-44.
Radoji MR, Thudium CS, Henriksen K, et al. Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients. Pain 2017;158:1254-63.
Huebner JL, Bay-Jensen AC, Huffman KM, et al. Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis. Arthritis Rheumatol 2014;66:2440-9.
Taylor J, Dekker S, Jurg D, et al. Making the patient voice heard in a research consortium: experiences from an EU project (IMI-APPROACH). Res Involv Engagem 2021;7:24.